When should unfractionated heparin be initiated after tenecteplase administration?

Heparin Initiation After Tenecteplase

Unfractionated heparin should be administered immediately with or immediately after the tenecteplase bolus—not delayed—using a weight-adjusted dose of 60 U/kg IV bolus (maximum 4,000 U) followed by 12 U/kg/hour infusion (maximum 1,000 U/hour), targeting an aPTT of 1.5–2.0 times control (50–70 seconds). 1

Standard UFH Protocol with Tenecteplase

The key principle is that heparin is given concurrently with fibrin-specific agents like tenecteplase, not sequentially. The ACC/AHA guidelines explicitly state that UFH "should be given intravenously to patients undergoing reperfusion therapy with alteplase, reteplase, or tenecteplase" with immediate dosing. 1 The FDA label for tenecteplase confirms this approach, stating "intravenous heparin was to be administered as soon as possible" in the pivotal ASSENT-2 trial. 2

Dosing Specifics

• Initial bolus: 60 U/kg IV (maximum 4,000 U for patients >70 kg) 1
• Maintenance infusion: 12 U/kg/hour (maximum 1,000 U/hour for patients >70 kg) 1
• Target aPTT: 1.5–2.0 times control, approximately 50–70 seconds 1
• Duration: Minimum 48 hours, preferably through hospitalization up to 8 days or until revascularization 1

Monitoring Requirements

• First aPTT check: 3 hours after initiation 1
• Subsequent checks: 6,12, and 24 hours, then 4–6 hours after any dose adjustment 3
• Platelet monitoring: Daily platelet counts to detect heparin-induced thrombocytopenia 1

Alternative: Enoxaparin (Age and Renal Function Dependent)

For patients <75 years with normal renal function, enoxaparin is an acceptable—and potentially superior—alternative to UFH. 1 The ASSENT-3 trial demonstrated that tenecteplase plus enoxaparin reduced ischemic complications compared to UFH, though with increased bleeding risk in elderly patients. 4

Enoxaparin Dosing for Patients <75 Years

• IV bolus: 30 mg immediately with tenecteplase 5
• Subcutaneous dose: 1.0 mg/kg every 12 hours, starting within 15 minutes of the IV bolus 5
• Duration: Until hospital discharge, maximum 8 days 5

Critical Contraindications for Enoxaparin

Enoxaparin is Class III (contraindicated) in two populations: 1

1. Age ≥75 years: The ASSENT-3 PLUS trial showed a 2.2% intracranial hemorrhage rate with enoxaparin versus 0.97% with UFH in elderly patients, driven entirely by the >75 age group. 6 If enoxaparin must be used in this age group, omit the IV bolus and reduce the subcutaneous dose to 0.75 mg/kg every 12 hours. 5

2. Significant renal dysfunction: Creatinine >2.5 mg/dL (men) or >2.0 mg/dL (women) 1 For creatinine clearance <30 mL/min, reduce to 1.0 mg/kg subcutaneously every 24 hours. 5

Evidence Supporting Immediate Heparin Administration

The weight-adjusted UFH regimen (60 U/kg bolus, 12 U/kg/hour infusion) was validated in ASSENT-3, which showed reduced major bleeding (2.2% vs 4.7%) and refractory ischemia (6.5% vs 8.6%) compared to the older weight-stratified dosing used in ASSENT-2. 7 The European Society of Cardiology 2008 guidelines reinforced this approach, stating anticoagulation should begin "as soon as possible" with fibrin-specific agents. 1

Common Pitfalls to Avoid

• Delaying heparin: There is no waiting period; heparin is given immediately with tenecteplase 1
• Underdosing the bolus: Failing to use weight-based dosing leads to subtherapeutic anticoagulation 1
• Premature discontinuation: Continue for at least 48 hours unless contraindicated; high-risk patients (large anterior MI, atrial fibrillation, known LV thrombus) may require longer duration 1
• Using enoxaparin in elderly patients: The >75 age cutoff is absolute based on intracranial hemorrhage risk 6
• Switching between UFH and enoxaparin: This increases bleeding risk and should be avoided 5

Special Populations

Heparin-Induced Thrombocytopenia

For patients with known HIT, bivalirudin is the preferred alternative: 0.25 mg/kg IV bolus followed by 0.5 mg/kg/hour for 12 hours, then 0.25 mg/kg/hour for 36 hours. 1 Reduce the infusion rate if aPTT exceeds 75 seconds. 1

High Systemic Embolic Risk

Patients at high risk for systemic emboli (large or anterior MI, atrial fibrillation, previous embolus, known LV thrombus) should receive UFH even if treated with non-fibrin-specific agents like streptokinase. 1 This represents a Class I indication for anticoagulation beyond the standard 48-hour minimum. 1